Medicure Inc. (MPH) EPS Estimated At $0.12

November 10, 2018 - By Hugh Holland

Analysts expect Medicure Inc. (CVE:MPH) to report $0.12 EPS on November, 20.They anticipate $0.06 EPS change or 100.00 % from last quarter’s $0.06 EPS. V_MPH’s profit would be $1.89M giving it 12.88 P/E if the $0.12 EPS is correct. After having $0.09 EPS previously, Medicure Inc.’s analysts see 33.33 % EPS growth. The stock decreased 1.90% or $0.12 during the last trading session, reaching $6.18. About 11,583 shares traded or 122.24% up from the average. Medicure Inc. (CVE:MPH) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Medicure Inc., a specialty pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, Barbados, and India. The company has market cap of $97.11 million. The firm primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome. It has a 2.23 P/E ratio. It is also developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: